Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 13/20 | 0.39 |
| ▸ | AKT2 | P31751 | 13/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536669 | 1.00 | AKT1 (0.39) | AKT1AKT2ALDH1A1POLBLMNA | |
| SCHEMBL25271560 | 0.94 | AKT1 (0.39) | AKT1AKT2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29536658 | 0.94 | AKT1 (0.39) | AKT1AKT2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25278070 | 0.88 | CYP1A2 (0.40) | AKT1AKT2ALDH1A1MAPTCYP1A2 | |
| SCHEMBL25271264 | 0.82 | AKT1 (0.34) | AKT1AKT2ALDH1A1MAPTHTT | |
| SCHEMBL29537498 | 0.82 | AKT1 (0.34) | AKT1AKT2ALDH1A1MAPTHTT | |
| SCHEMBL27103103 | 0.80 | FLT3 (0.39) | ALDH1A1POLBLMNAMAPTEGFR | |
| SCHEMBL25227902 | 0.80 | CDK1 (0.39) | AKT1AKT2CDK2 | |
| SCHEMBL24271449 | 0.80 | AKT1 (0.34) | AKT1AKT2CYP3A4CYP2D6CDK2 | |
| SCHEMBL25227955 | 0.80 | CDK1 (0.39) | AKT1AKT2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043350-A1 | TRIAZOLOPYRIDOPYRIMIDINE AND DIHYDROIMIDAZOPYRIDOPYRIMIDINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2025-03-06 | — | — | WO | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | AKT1 59/4885AKT2 86/4885ALDH1A1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.